Develops and markets prescription pharmaceuticals for various health conditions. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
No real growth. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 1.1× for every dollar of annual revenue.
No analyst target is on record for this company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are going backwards, not just slowing.
The stock trades 24% below its peak. The market has trimmed its expectations for the company.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
It pays out $0.03 per share each year — regular cash for whoever holds the stock.
A loss of $4.0B against $50.8B in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts about 2.3 years. After that, the company needs to find new money.
Against everything we grade, BAYRY lands somewhere in the middle. The grade moves as the numbers move.
The takeaway: BAYRY’s sales are going backwards, and it closed last year at a loss. The road back runs through both.
Not covered, because the filings we hold do not carry it: the revenue breakdown.